Merck Says Additional Information Provided to Investigators in Clinical Study of Vorapaxar

Commenting on the new communication, Dr. Braunwald said, In contrast, on the basis of their risk/benefit assessment in patients without a history of stroke, the DSMB recommended to us that it is important that the trial continue to completion in the more than 20,000 subjects who qualified for the tr...

Full description

Saved in:
Bibliographic Details
Published inBusiness Wire
Format Newsletter
LanguageEnglish
Published New York Business Wire 19.01.2011
Subjects
Acute coronary syndromes
Communication
Health care policy
Heart attacks
Ischemia
Regulation of financial institutions
Safe harbor
Stroke
Studies
United States > US
WHITEHOUSE STATION, N.J
Online AccessGet full text

Cover

More Information
Summary:Commenting on the new communication, Dr. Braunwald said, In contrast, on the basis of their risk/benefit assessment in patients without a history of stroke, the DSMB recommended to us that it is important that the trial continue to completion in the more than 20,000 subjects who qualified for the trial with myocardial infarction or peripheral arterial disease who have not had a stroke. TRA-2P, or TIMI 50, is a chronic care, secondary prevention study of approximately 26,500 patients who have experienced a heart attack, an ischemic stroke, or have documented peripheral vascular disease.